Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Motif Bio Receives Complete Response Letter from the FDA

Motif Bio plc announced today that the clinical-stage biopharmaceutical company received a complete response letter from the U.S. Food and Drug Administration regarding the new drug application for iclaprim for the treatment of acute bacterial skin and skin structure infections.

Read More »

Prior dengue infection may protect against Zika: study

Prior infection with dengue, a mosquito-borne disease that infects nearly 400 million people a year, could reduce the risk of contracting Zika nearly by half, U.S. and Brazilian researchers reported.

Read More »

Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting

Cidara Therapeutics Inc. announced that data from studies of the biotechnology company’s lead antifungal rezafungin will be presented at the 2019 Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and CIBMTR to be held in Houston from Feb. 20-24.

Read More »

Takeda dengue vaccine meets main study goal of trial

Takeda Pharmaceutical’s experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquito-borne disease, meeting the main goal of a late-stage clinical trial.

Read More »

U.S. FDA Accepts sNDAs for Pifeltro and Delstrigo

Merck & Co. announced that the U.S. Food and Drug Administration accepted for review supplemental New Drug Applications (sNDAs) for Pifeltro and Delstrigo.

Read More »

Chinese Government Takes Action Against CRISPR Researcher

China government officials told the Xinhua News Agency that the researcher who became world famous for using CRISPR on human embryos “will be transferred to public security authorities,” and the individuals involved in the research will be “severely dealt with according to the law.”

Read More »

NYU and Janssen Develop New Class of Proteins to Fight Antibiotic-Resistant Infections

Researchers at New York University School of Medicine and Janssen Research & Development, a Johnson & Johnson company, developed a new class of engineered proteins that may help fight the bacteria that cause Staph infections.

Read More »

Johns Hopkins, Bristol-Myers must face $1 billion syphilis infections lawsuit

A federal judge in Maryland said The Johns Hopkins University, Bristol-Myers Squibb Co. and the Rockefeller Foundation must face a $1 billion lawsuit over their roles in a 1940s U.S. government experiment that infected hundreds of Guatemalans with syphilis.

Read More »

Locus and Janssen Ink Potential $818 Million Deal

Locus Biosciences inked a collaboration and license deal with J&J’s Janssen Pharmaceutical to develop precision antibacterial therapies based on CRISPR-Cas3-enhanced bacteriophage.

Read More »

To Infinity and Beyond! Emulate’s Intestine-Chip Heads to the International Space Station

Emulate won a $2 million grant from the National Institutes of Health (NIH)’s National Center for Advancing Translational Sciences, to be used to send one of the Boston-based company’s Organ-Chips to the International Space Station in March 2019.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom